Clinical Trial

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-11-18; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2025-03-13
Trial Details
NCT Number NCT06697301
Lead Sponsor Eikon Therapeutics
Collaborators: Merck Sharp & Dohme LLC
Conditions Advanced Melanoma
Enrollment 740 participants
Start Date 2025-05-22
Primary Completion 2035-12 (estimated)
Study Completion 2040-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-08